• Vaccine Name: PfP0 P-BSA
• Target Pathogen: Plasmodium spp.
• Target Disease: Malaria
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Human
• Antigen: PfP0 P peptide: 16-amino-acid C-terminal peptide sequence of ribosomal phosphoprotein P0 of P. falciparum (Rajeshwari et al., 2004)
• PfP0 gene engineering:
  • Type: Recombinant protein preparation
  • Description: PfP0 P peptide was coupled to BSA (PfP0 P-BSA) using glutaraldehyde (Rajeshwari et al., 2004)
  • Detailed Gene Information: Click Here.
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: Swiss mice (Rajeshwari et al., 2004)
• Host age: 8-week-old (Rajeshwari et al., 2004)
• Host gender: female (Rajeshwari et al., 2004)
• Vaccination Protocol: Mice were injected intraperitoneally with PfP0 P-BSA conjugate in Freund's adjuvant at 21-day intervals. In one control group, mice were injected in parallel with PBS emulsified in Freund's adjuvant. The other control group received no injections. The titers of the anti-PfP0 antibodies were measured after five immunizations. (Rajeshwari et al., 2004)
• Challenge Protocol: The mice were challenged with P. yoelii (106 parasites per mouse) after 5 immunizations. (Rajeshwari et al., 2004)
• Efficacy: Two of the six mice immunized with PfP0 P peptide developed parasitemia, compared with all 14 mice developed parasitemia in the control. One immunized mouse showed parasitemia on day 7 and died on day 8, and the other mouse showed parasitemia on day 14 but recovered by day 31, while all controls developed parasitemia by the sixth day postchallenge. The mean parasitemia levels of the three groups were statistically significantly different on day 9 (P < 0.0001), day 11 (P = 0.0014), day 13 (P = 0.0007), day 15 (P = 0.003), and day 17(P = 0.023). (Rajeshwari et al., 2004)